Li-Ping Mao Selected Research

Decitabine

1/2016

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Li-Ping Mao Research Topics

Disease

3	Neoplasms (Cancer) 07/2021 - 10/2008
2	Leukemia 02/2018 - 01/2016
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2016 - 01/2008
1	Acute Promyelocytic Leukemia 10/2022
1	Stomach Neoplasms (Stomach Cancer) 07/2021
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2018
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2016
1	Hepatolenticular Degeneration (Wilson's Disease) 01/2015
1	Brain Diseases (Brain Disorder) 01/2015

Drug/Important Bio-Agent (IBA)

2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2016 - 01/2008
1	ArsenicIBA 10/2022
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 10/2022
1	Arsenic Trioxide (Trisenox)FDA Link 10/2022
1	Zinc Oxide FDA Link 07/2021
1	Beclin-1IBA 02/2018
1	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2018
1	Decitabine FDA Link 01/2016
1	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2016
1	CopperIBA 01/2015
1	Proteins (Proteins, Gene)FDA Link 10/2008
1	HomoharringtonineIBA 01/2008
1	AclarubicinIBA 01/2008

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 02/2018 - 01/2016
1	Induction Chemotherapy 01/2008